Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.

Autor: Alam F; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Gaspari TA; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Kemp-Harper BK; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Low E; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Aw A; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Ferens D; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Spizzo I; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Jefferis AM; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Praveen P; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia., Widdop RE; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia., Bathgate RAD; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria, Australia., Hossain MA; Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia; School of Chemistry, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: akhter.hossain@unimelb.edu.au., Samuel CS; Cardiovascular Disease Program, Monash Biomedicine Discovery Institute and Department of Pharmacology, Monash University, Clayton, Victoria, Australia; Department of Biochemistry and Pharmacology, The University of Melbourne, Parkville, Victoria, Australia. Electronic address: chrishan.samuel@monash.edu.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2023 Apr; Vol. 160, pp. 114370. Date of Electronic Publication: 2023 Feb 06.

Chronic sympathetic driven hypertension promotes atherosclerosis by enhancing hematopoiesis.

Autor: Al-Sharea A; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia andrew.murphy@baker.edu.au annas.al-sharea@baker.edu.au., Lee MKS; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Whillas A; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Michell DL; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA., Shihata WA; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Department of Pharmacology, Monash University, Clayton, VIC, Australia., Nicholls AJ; Monash University, Melbourne, VIC, Australia., Cooney OD; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Kraakman MJ; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Naomi Berrie Diabetes Center and Department of Medicine, Columbia University, New York, NY, USA., Veiga CB; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Jefferis AM; Department of Pharmacology, Monash University, Clayton, VIC, Australia., Jackson K; Neuropharmacology Laboratory, Division of Hypertension and Cardiac Disease, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Nagareddy PR; Department of Nutrition Sciences, University of Alabama at Birmingham, AL, USA., Lambert G; Human Neurotransmitters Laboratory, Division of Hypertension and Cardiac Disease, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia.; Iverson Health Innovation Research Institute, Swinburne University of Technology, Hawthorn, VIC, Australia., Wong CHY; Monash University, Melbourne, VIC, Australia., Andrews KL; Department of Pharmacology, Monash University, Clayton, VIC, Australia., Head GA; Neuropharmacology Laboratory, Division of Hypertension and Cardiac Disease, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia., Chin-Dusting J; Department of Pharmacology, Monash University, Clayton, VIC, Australia., Murphy AJ; Haematopoiesis and Leukocyte Biology Laboratory, Division of Immunometabolism, Baker Heart and Diabetes Institute, Melbourne, VIC, Australia andrew.murphy@baker.edu.au annas.al-sharea@baker.edu.au.; Department of Immunology, Monash University, Melbourne, VIC, Australia.

Publikováno v: Haematologica [Haematologica] 2019 Mar; Vol. 104 (3), pp. 456-467. Date of Electronic Publication: 2018 Oct 25.

Y-chromosome lineage determines cardiovascular organ T-cell infiltration in the stroke-prone spontaneously hypertensive rat.

Autor: Khan SI; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.; Department of Medicine, Monash University, Melbourne, Victoria, Australia.; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Andrews KL; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Jackson KL; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Memon B; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Jefferis AM; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Lee MKS; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Diep H; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia., Wei Z; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia., Drummond GR; Department of Physiology, Anatomy, and Microbiology, La Trobe University, Bundoora, Victoria, Australia., Head GA; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Jennings GL; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.; Sydney Medical School, University of Sydney, Camperdown, New South Wales, Australia., Murphy AJ; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Vinh A; Department of Physiology, Anatomy, and Microbiology, La Trobe University, Bundoora, Victoria, Australia., Sampson AK; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia., Chin-Dusting JPF; Department of Pharmacology, Biomedicine Discovery Institute, Monash University, Clayton, Victoria, Australia.; Department of Medicine, Monash University, Melbourne, Victoria, Australia.; Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Publikováno v: FASEB journal : official publication of the Federation of American Societies for Experimental Biology [FASEB J] 2018 May; Vol. 32 (5), pp. 2747-2756. Date of Electronic Publication: 2018 Jan 04.

Nitroxyl: a vasodilator of human vessels that is not susceptible to tolerance.

Autor: Andrews KL; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Lumsden NG; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Farry J; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Jefferis AM; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia., Kemp-Harper BK; †Vascular Biology and Immunopharmacology Group, Department of Pharmacology, Monash University, Clayton, Victoria 3800, Australia., Chin-Dusting JP; Vascular Pharmacology Laboratory, Baker IDI Heart and Diabetes Institute, Melbourne, Victoria 3004, Australia.

Publikováno v: Clinical science (London, England : 1979) [Clin Sci (Lond)] 2015 Jul; Vol. 129 (2), pp. 179-87.